Elvira O Gosmanova1, Miklos Z Molnar2, Adnan Naseer3, Keiichi Sumida4, Praveen Potukuchi4, Abduzhappar Gaipov5, Barry M Wall3, Fridtjof Thomas6, Elani Streja7, Kamyar Kalantar-Zadeh7, Csaba P Kovesdy8. 1. Nephrology Section, Stratton VA Medical Center, Albany, New York; Division of Nephrology, Department of Medicine, Albany Medical College, Albany, New York. 2. Division of Nephrology, Department of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee; Division of Transplantation, Department of Surgery, University of Tennessee Health Science Center, Memphis, Tennessee; Methodist University Hospital Transplant Institute, Memphis, Tennessee. 3. Division of Nephrology, Department of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee; Nephrology Section, Memphis VA Medical Center, Memphis, Tennessee. 4. Division of Nephrology, Department of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee. 5. Department of Medicine, Nazarbayev University School of Medicine, Nur-Sultan, Republic of Kazakhstan. 6. Division of Biostatistics, Department of Preventive Medicine, College of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee. 7. Harold Simmons Center for Kidney Disease Research and Epidemiology, Division of Nephrology and Hypertension, University of California Irvine Medical Center, Orange, California; Nephrology Section, Tibor Rubin Veterans Affairs Medical Center, Long Beach, California. 8. Division of Nephrology, Department of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee; Nephrology Section, Memphis VA Medical Center, Memphis, Tennessee. Electronic address: ckovesdy@uthsc.edu.
Abstract
BACKGROUND: Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers (ACEi/ARB) improve predialysis outcomes; however, ACEi/ARB are underused in patients transitioning to dialysis. We examined the association of different patterns of predialysis ACEi/ARB use with postdialysis survival and whether potentially modifiable adverse events are associated with lower predialysis ACEi/ARB use. METHODS: This was a historic cohort study of 34,676 US veterans with, and 10,690 without, ACEi/ARB exposure in the 3-year predialysis period who subsequently transitioned to dialysis between 2007 and 2014. Associations of different patterns of predialysis ACEi/ARB use with postdialysis all-cause mortality and with predialysis acute kidney injury and hyperkalemia events were examined using multivariable adjusted regression analyses. RESULTS: The mean age of the cohort was 70 years, 98% were males and 27% were African Americans. Compared to ACEi/ARB nonuse, continuous ACEi/ARB use was associated with lower postdialysis all-cause mortality (adjusted hazard ratio [aHR]; 95% confidence interval [95% CI] 0.87; 0.83-0.92). In analyses modeling the duration of predialysis ACEi/ARB use, ACEi/ARB use of 50%-74% and ≥75% were associated with lower mortality compared to nonuse (adjusted hazard ratio, 95% confidence interval 0.96, 0.92-0.99 and 0.91; 0.88-0.94, respectively), whereas no increase in postdialysis survival was observed with shorter predialysis ACEi/ARB use. Predialysis acute kidney injury was associated with shorter duration (<50%) of ACEi/ARB use and hyperkalemia was associated with interrupted and ACEi/ARB use of <75%. CONCLUSIONS: Longer predialysis ACEi/ARB exposure was associated with lower postdialysis mortality. Prospective studies are needed to evaluate the benefits of strategies enabling uninterrupted predialysis ACEi/ARB use. Published by Elsevier Inc.
BACKGROUND:Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers (ACEi/ARB) improve predialysis outcomes; however, ACEi/ARB are underused in patients transitioning to dialysis. We examined the association of different patterns of predialysis ACEi/ARB use with postdialysis survival and whether potentially modifiable adverse events are associated with lower predialysis ACEi/ARB use. METHODS: This was a historic cohort study of 34,676 US veterans with, and 10,690 without, ACEi/ARB exposure in the 3-year predialysis period who subsequently transitioned to dialysis between 2007 and 2014. Associations of different patterns of predialysis ACEi/ARB use with postdialysis all-cause mortality and with predialysis acute kidney injury and hyperkalemia events were examined using multivariable adjusted regression analyses. RESULTS: The mean age of the cohort was 70 years, 98% were males and 27% were African Americans. Compared to ACEi/ARB nonuse, continuous ACEi/ARB use was associated with lower postdialysis all-cause mortality (adjusted hazard ratio [aHR]; 95% confidence interval [95% CI] 0.87; 0.83-0.92). In analyses modeling the duration of predialysis ACEi/ARB use, ACEi/ARB use of 50%-74% and ≥75% were associated with lower mortality compared to nonuse (adjusted hazard ratio, 95% confidence interval 0.96, 0.92-0.99 and 0.91; 0.88-0.94, respectively), whereas no increase in postdialysis survival was observed with shorter predialysis ACEi/ARB use. Predialysis acute kidney injury was associated with shorter duration (<50%) of ACEi/ARB use and hyperkalemia was associated with interrupted and ACEi/ARB use of <75%. CONCLUSIONS: Longer predialysis ACEi/ARB exposure was associated with lower postdialysis mortality. Prospective studies are needed to evaluate the benefits of strategies enabling uninterrupted predialysis ACEi/ARB use. Published by Elsevier Inc.
Authors: Sandeep Brar; Feng Ye; Matthew T James; Brenda Hemmelgarn; Scott Klarenbach; Neesh Pannu Journal: JAMA Intern Med Date: 2018-12-01 Impact factor: 21.873
Authors: Rajiv Agarwal; Arjun D Sinha; Maria K Pappas; Terri N Abraham; Getachew G Tegegne Journal: Nephrol Dial Transplant Date: 2014-01-06 Impact factor: 5.992
Authors: Inder S Anand; Kalkidan Bishu; Thomas S Rector; Areef Ishani; Michael A Kuskowski; Jay N Cohn Journal: Circulation Date: 2009-10-05 Impact factor: 29.690
Authors: Alan K Berger; Sue Duval; Connie Manske; Gabriela Vazquez; Cheryl Barber; Leslie Miller; Russell V Luepker Journal: Am Heart J Date: 2007-06 Impact factor: 4.749
Authors: Carl P Walther; Wolfgang C Winkelmayer; Peter A Richardson; Salim S Virani; Sankar D Navaneethan Journal: Nephrol Dial Transplant Date: 2021-09-27 Impact factor: 7.186